GEMCITABINE HYDROCHLORIDE | N209604 | ACCORD HEALTHCARE INC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 3 | Active | AstraZeneca | 825 | 2018-12-06 → 2028-09-11 | |
| Phase 1 | Active | Eli Lilly and Company | 223 | 2016-11-21 → 2027-08 | |
| Phase 1 | Active | National Cancer Institute (NCI) | 55 | 2009-03-31 → 2027-03-06 | |
| Phase 3 | Active | Janssen Research & Development, LLC | 518 | 2020-12-07 → 2028-12-31 | |
| Phase 2 | Active | Anne Noonan | 67 | 2020-06-24 → 2026-12-31 | |
| Phase 1 | Active | University of Southern California | 61 | 2015-09-03 → 2026-12-31 | |
| Phase 2/3 | Active | NRG Oncology | 924 | 2014-07-01 → 2034-01-01 | |
| Phase 2 | Active | The First Hospital of Jilin University | 62 | 2026-07-30 → 2028-12-31 | |
| Phase 3 | Active | Arcus Biosciences, Inc. | 610 | 2024-12-13 → 2030-11-30 | |
| Phase 2 | Active | Roland Seiler-Blarer | 31 | 2023-02-21 → 2028-12-31 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
Lowest Price
$1.37
Highest Price
$28.14
FSS NDCs
7
Big4 NDCs
3
| Description | Price | Type | Vendor | Contract End |
|---|---|---|---|---|
| 68001-0342-34GEMCITABINE 100MG/ML INJ,SOLN | $2.78 | Big4 | Amerisource Health Services LLC dba American Health Packaging | 09/14/2028 |
| 68001-0342-34GEMCITABINE 100MG/ML INJ,SOLN | $4.02 | FSS | Amerisource Health Services LLC dba American Health Packaging | 09/14/2028 |
| 68001-0348-36GEMCITABINE 100MG/ML INJ,SOLN | $7.39 | Big4 | Amerisource Health Services LLC dba American Health Packaging | 09/14/2028 |
| 68001-0348-36GEMCITABINE 100MG/ML INJ,SOLN | $14.07 | FSS | Amerisource Health Services LLC dba American Health Packaging | 09/14/2028 |
| 68001-0359-37GEMCITABINE 100MG/ML INJ,SOLN | $16.88 | Big4 | Amerisource Health Services LLC dba American Health Packaging | 09/14/2028 |
| 68001-0359-37GEMCITABINE 100MG/ML INJ,SOLN | $28.14 | FSS | Amerisource Health Services LLC dba American Health Packaging | 09/14/2028 |
Showing 6 of 10 NDCs.
Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.
16 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Sep 26, 2024 | SUPPL -11 | View Letter (PDF) |
| Jun 26, 2019 | SUPPL -4 | View Letter (PDF) |
| Dec 21, 2018 | SUPPL -2 | View Letter (PDF) |
| Aug 3, 2018 | SUPPL -3 | View Letter (PDF) |
| Aug 7, 2017 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.